We tested the effect of co-treatment of acromegaly with a somatostatin analogue (SA) and a growth hormone receptor antagonist (GHA). Eleven patients underwent: 1) conventional treatment with SA, 2) discontinued treatment, 3) 6 weeks treatment with GHA (10 mg), 4) 6 weeks treatment with GHA (15 mg), 5) 3 months combined SA and GHA. Circulating IGF-I was lowered by GHA and more so with combined treatment. Treatment with GHA increased endogenous GH levels, which was partly reversed by combined treatment. Plasma glucose levels were highest during SA treatment and lowest with GHA. Co-treatment of acromegaly with SA and GHA is a promising concept.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis.
Pituitary
February 2023
Department of Endocrinology and Metabolism, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Purpose: Active acromegaly is associated with impaired glucose metabolism, which improves upon treatment. Treatment options include surgery, medical therapy with somatostatin analogues (SSA) and Pegvisomant (PEG), and irradiation. The objective of the study was to describe the differential effect of various treatment regimens on the secretion of glucose, insulin, glucagon, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) in patients with acromegaly.
View Article and Find Full Text PDFThe effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.
Growth Horm IGF Res
June 2009
Medizinische Klinik-Innenstadt, University of Munich, Endokrinologie, München, Germany.
Objective: Co-treatment with somatostatin analogues and growth hormone receptor antagonists in acromegaly might be a new treatment option abolishing the negative effects of monotherapy. Nevertheless, little is known about the acute effect of the combined treatment on endogenous GH and pegvisomant levels.
Design: Ten acromegalic patients on constant pegvisomant therapy were included.
[Medical co-treatment af acromegaly with a somatostatin analogue and a growth hormone receptor antagonist].
Ugeskr Laeger
March 2007
Arhus Universitetshospital, Arhus Sygehus, Medicinsk Afdeling M, Arhus C.
We tested the effect of co-treatment of acromegaly with a somatostatin analogue (SA) and a growth hormone receptor antagonist (GHA). Eleven patients underwent: 1) conventional treatment with SA, 2) discontinued treatment, 3) 6 weeks treatment with GHA (10 mg), 4) 6 weeks treatment with GHA (15 mg), 5) 3 months combined SA and GHA. Circulating IGF-I was lowered by GHA and more so with combined treatment.
View Article and Find Full Text PDFIn vivo evaluation of a novel, orally bioavailable, small molecule growth hormone receptor antagonist.
Growth Horm IGF Res
February 2007
Discovery Research, Biovitrum AB, S-112 76 Stockholm, Sweden.
IGF-I is regarded as the most sensitive marker of growth hormone (GH) secretion in both GH deficient individuals and in individuals with excessive GH production. Studies on the effect of inhibitors of GH action in normal experimental animals are difficult to evaluate due to the complex relationship and feed back mechanisms of the GH/IGF-I system and the hypothalamo-pituitary axis. To circumvent the GH/IGF-I feedback mechanisms, we have used hypophysectomized (HX) rats treated with GH to assess the potential of a new low molecular weight compound, BVT-A ((N-[5-(aminosulfonyl)-2-methylphenyl]-5-bromo-2-furamide), to act as a GH receptor antagonist in vivo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!